74 results
Page 2 of 4
8-K
EX-99.1
0nundztmqmfpyk
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
8-K
EX-99.1
d2v1dmqpgbzmz1 ko
10 Nov 21
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
4:05pm
8-K
EX-99.1
wey7g3 m59ivp
5 Aug 21
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
5:31pm
8-K
EX-99.1
4dk3i18fyuzt6kz0l
13 May 21
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
7:34am
8-K
EX-99.1
9nrik 4ian7la
29 Mar 21
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
5:26pm
8-K
EX-99.1
jr6z4szgmorgfv9
16 Nov 20
Windtree Therapeutics Reports Third Quarter 2020
7:40am
8-K
EX-99.1
5mx245
1 Oct 20
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
7:36am
8-K
EX-99.1
unqwushzkja
29 Sep 20
Other Events
7:37am
8-K
EX-99.1
xj3dred
14 Aug 20
Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates
6:07am
8-K
EX-99.2
r66gjmizs6g8rc8l
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.1
n71ltsp4rs7k
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
424B4
y3m5l
21 May 20
Prospectus supplement with pricing info
6:04am
8-K
EX-99.1
g3suawmsi0rbfl u7f0
14 May 20
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
8:12am
S-1/A
xkt3ot0sifg184k22g
6 May 20
IPO registration (amended)
5:31pm